SEC Form 4 · accession 0001652252-17-000116
BIO-RAD LABORATORIES, INC. · BIO BIO.B
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christine A Tsingos
Officer — EVP and CFO
Period of report
Dec 14, 2017
Accepted (ET)
Dec 14, 2017 · 7:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000012208
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Bio-Rad A Common Stock | Dec 14, 2017 | M | 600 | $98.04 | A | 7,283 | D | |
| Bio-Rad A Common Stock | Dec 14, 2017 | M | 1,300 | $107.32 | A | 8,583 | D | |
| Bio-Rad A Common Stock | Dec 14, 2017 | M | 1,280 | $117.00 | A | 9,863 | D | |
| Bio-Rad A Common Stock | Dec 14, 2017 | M | 800 | $119.54 | A | 10,663 | D | |
| Bio-Rad A Common Stock | Dec 14, 2017 | M | 1,000 | $139.56 | A | 11,663 | D | |
| Bio-Rad A Common StockF1 | Dec 14, 2017 | S | 4,980 | $249.4016 | D | 6,683 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $98.04 | Dec 14, 2017 | M | 600 | D | — | Nov 4, 2021 | Bio-Rad A Common Stock | 600 | 0 | D |
| Non-Qualified Stock Option (right to buy)F3 | $107.32 | Dec 14, 2017 | M | 1,300 | D | — | Sep 12, 2022 | Bio-Rad A Common Stock | 1,300 | 0 | D |
| Non-Qualified Stock Option (right to buy)F4 | $117.00 | Dec 14, 2017 | M | 1,280 | D | — | Sep 11, 2023 | Bio-Rad A Common Stock | 1,280 | 640 | D |
| Non-Qualified Stock Option (right to buy)F5 | $119.54 | Dec 14, 2017 | M | 800 | D | — | Sep 10, 2024 | Bio-Rad A Common Stock | 800 | 800 | D |
| Non-Qualified Stock Option (right to buy)F6 | $139.56 | Dec 14, 2017 | M | 1,000 | D | — | Sep 11, 2025 | Bio-Rad A Common Stock | 1,000 | 1,500 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $249.15 to $249.54, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The option vested in five equal annual installments beginning November 4, 2012.
- F3The option vested in five equal annual installments beginning September 12, 2013
- F4The option vested in five equal annual installments beginning September 11, 2014.
- F5The option vested in five equal annual installments beginning September 10, 2015.
- F6The option vested in five equal annual installments beginning September 11, 2016.